Details for New Drug Application (NDA): 202179

✉ Email this page to a colleague

NDA 202179 describes PREDNISOLONE SODIUM PHOSPHATE, which is a drug marketed by Watson Labs, Alcon Pharms Ltd, Bausch And Lomb, Epic Pharma Llc, Sola Barnes Hind, Amneal, Amneal Pharms, Bausch, Chartwell Rx, Edenbridge Pharms, Endo Operations, Hikma, Mission Pharma, Nesher Pharms, Pharm Assoc, Pharmobedient Cnsltg, Vintage Pharms, We Pharms, Xttrium Labs Inc, and Rising, and is included in thirty NDAs. It is available from eleven suppliers. Additional details are available on the PREDNISOLONE SODIUM PHOSPHATE profile page.

The generic ingredient in PREDNISOLONE SODIUM PHOSPHATE is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

Tradename:	PREDNISOLONE SODIUM PHOSPHATE
Applicant:	Rising
Ingredient:	prednisolone sodium phosphate
Patents:	0

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	EQ 10MG BASE
Approval Date:	Apr 10, 2013	TE:		RLD:	No

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	EQ 15MG BASE
Approval Date:	Apr 10, 2013	TE:		RLD:	No

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	EQ 30MG BASE
Approval Date:	Apr 10, 2013	TE:		RLD:	No

Complete Access Available with Subscription